Neoadjuvant endocrine treatment in primary breast cancer - Review of literature

作者：Mathew J^*; Asgeirsson K S; Jackson L R; Cheung K L; Robertson J F R

来源：Breast, 2009, 18(6): 339-344.

DOI：10.1016/j.breast.2009.09.012

• Neoadjuvant endocrine treatment
• Clinical response
• Breast conservation surgery

Chemotherapeutic agents have dominated neoadjuvant treatment compared to endocrine agents in the past and have demonstrated their ability to produce tumour shrinkage to allow breast conservation. However, in the more recent setting, studies have been emerging with the use of aromatase inhibitors, especially comparing its use with tamoxifen in selected group of patients.
The role of tamoxifen in its ability to achieve tumour shrinkage has been evaluated in the past, and has shown to produce slow but sustained response. Aromatase inhibitors have shown superiority over tamoxifen in adjuvant and metastatic setting, and the aim of our study was to compare their outcome with regard to response and breast conservation in the neoadjuvant setting. We also looked into optimum duration of neoadjuvant treatment and also the role of pathological complete response as a surrogate marker for clinical outcome.
Our review highlights the superiority of aromatase inhibitors over tamoxifen in the neoadjuvant setting and even challenges chemotherapy with regard to response in selected group of patients.

• 出版日期2009-12